Which has higher earnings and valuation, PMN or AVIR?

Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Promis Neurosciences N/A N/A -$39.72M -$14.51 N/A Atea Pharmaceuticals N/A N/A -$158.35M -$2.11 N/A

Is PMN or AVIR more profitable?

Atea Pharmaceuticals' return on equity of -57.01% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Promis Neurosciences N/A -237.99% -151.04% Atea Pharmaceuticals N/A -57.01% -51.49%

Which has preferable valuation & earnings, LXEO or PMN?

Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lexeo Therapeutics N/A N/A -$99.96M -$1.45 N/A Promis Neurosciences N/A N/A -$39.72M -$14.51 N/A

Is LXEO or PMN more profitable?

Lexeo Therapeutics' return on equity of -47.48% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Lexeo Therapeutics N/A -47.48% -41.72% Promis Neurosciences N/A -237.99% -151.04%

Do analysts recommend ELYM or PMN?

Promis Neurosciences has a consensus price target of $26.50, suggesting a potential upside of 156.04%. Given Promis Neurosciences' stronger consensus rating and higher possible upside, analysts plainly believe Promis Neurosciences is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Promis Neurosciences 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60

Which has stronger earnings and valuation, ELYM or PMN?

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eliem Therapeutics N/A N/A -$35.12M -$0.53 N/A Promis Neurosciences N/A N/A -$39.72M -$14.51 N/A

Is ELYM or PMN more profitable?

Eliem Therapeutics' return on equity of -47.03% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Eliem Therapeutics N/A -47.03% -45.97% Promis Neurosciences N/A -237.99% -151.04%

Promis Neurosciences (PMN) Competitors

$10.35 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$10.38 +0.03 (+0.24%)

As of 06/12/2026 04:10 PM Eastern

Compare

PMN vs. AVIR, IRD, LXEO, ELYM, and ENTA

Should you buy Promis Neurosciences stock or one of its competitors? MarketBeat compares Promis Neurosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Promis Neurosciences include Atea Pharmaceuticals (AVIR), Opus Genetics (IRD), Lexeo Therapeutics (LXEO), Eliem Therapeutics (ELYM), and Enanta Pharmaceuticals (ENTA). These companies are all part of the "pharmaceutical products" industry.

How does Promis Neurosciences compare to Atea Pharmaceuticals?

Promis Neurosciences (NASDAQ:PMN) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A

Promis Neurosciences has a beta of -0.19, suggesting that its share price is 119% less volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market.

Promis Neurosciences presently has a consensus price target of $26.50, indicating a potential upside of 156.04%. Given Promis Neurosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Promis Neurosciences is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Promis Neurosciences had 11 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 12 mentions for Promis Neurosciences and 1 mentions for Atea Pharmaceuticals. Promis Neurosciences' average media sentiment score of 0.75 beat Atea Pharmaceuticals' score of 0.43 indicating that Promis Neurosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Promis Neurosciences	Positive
Atea Pharmaceuticals	Neutral

50.1% of Promis Neurosciences shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 1.5% of Promis Neurosciences shares are owned by insiders. Comparatively, 21.6% of Atea Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Atea Pharmaceuticals' return on equity of -57.01% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Promis Neurosciences	N/A	-237.99%	-151.04%
Atea Pharmaceuticals	N/A	-57.01%	-51.49%

Summary

Promis Neurosciences beats Atea Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Promis Neurosciences compare to Opus Genetics?

Promis Neurosciences (NASDAQ:PMN) and Opus Genetics (NASDAQ:IRD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

Promis Neurosciences has higher earnings, but lower revenue than Opus Genetics. Opus Genetics is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A
Opus Genetics	$14.20M	23.49	-$49.59M	-$1.33	N/A

Promis Neurosciences has a beta of -0.19, indicating that its share price is 119% less volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

Promis Neurosciences presently has a consensus target price of $26.50, indicating a potential upside of 156.04%. Opus Genetics has a consensus target price of $10.67, indicating a potential upside of 164.03%. Given Opus Genetics' stronger consensus rating and higher possible upside, analysts plainly believe Opus Genetics is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Promis Neurosciences has a net margin of 0.00% compared to Opus Genetics' net margin of -892.36%. Promis Neurosciences' return on equity of -237.99% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Promis Neurosciences	N/A	-237.99%	-151.04%
Opus Genetics	-892.36%	-338.88%	-191.21%

50.1% of Promis Neurosciences shares are owned by institutional investors. Comparatively, 15.0% of Opus Genetics shares are owned by institutional investors. 1.5% of Promis Neurosciences shares are owned by insiders. Comparatively, 11.7% of Opus Genetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Promis Neurosciences had 4 more articles in the media than Opus Genetics. MarketBeat recorded 12 mentions for Promis Neurosciences and 8 mentions for Opus Genetics. Opus Genetics' average media sentiment score of 0.83 beat Promis Neurosciences' score of 0.75 indicating that Opus Genetics is being referred to more favorably in the news media.

Company	Overall Sentiment
Promis Neurosciences	Positive
Opus Genetics	Positive

Summary

Opus Genetics beats Promis Neurosciences on 8 of the 15 factors compared between the two stocks.

How does Promis Neurosciences compare to Lexeo Therapeutics?

Lexeo Therapeutics (NASDAQ:LXEO) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

60.7% of Lexeo Therapeutics shares are held by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are held by institutional investors. 2.0% of Lexeo Therapeutics shares are held by insiders. Comparatively, 1.5% of Promis Neurosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Lexeo Therapeutics presently has a consensus target price of $20.14, suggesting a potential upside of 360.93%. Promis Neurosciences has a consensus target price of $26.50, suggesting a potential upside of 156.04%. Given Lexeo Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Lexeo Therapeutics is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A

Lexeo Therapeutics has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.19, suggesting that its share price is 119% less volatile than the broader market.

Lexeo Therapeutics' return on equity of -47.48% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-47.48%	-41.72%
Promis Neurosciences	N/A	-237.99%	-151.04%

In the previous week, Promis Neurosciences had 11 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 12 mentions for Promis Neurosciences and 1 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 1.87 beat Promis Neurosciences' score of 0.75 indicating that Lexeo Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Lexeo Therapeutics	Very Positive
Promis Neurosciences	Positive

Summary

Lexeo Therapeutics beats Promis Neurosciences on 10 of the 13 factors compared between the two stocks.

How does Promis Neurosciences compare to Eliem Therapeutics?

Eliem Therapeutics (NASDAQ:ELYM) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A

Eliem Therapeutics' return on equity of -47.03% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
Promis Neurosciences	N/A	-237.99%	-151.04%

In the previous week, Promis Neurosciences had 12 more articles in the media than Eliem Therapeutics. MarketBeat recorded 12 mentions for Promis Neurosciences and 0 mentions for Eliem Therapeutics. Promis Neurosciences' average media sentiment score of 0.75 beat Eliem Therapeutics' score of 0.00 indicating that Promis Neurosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Eliem Therapeutics	Neutral
Promis Neurosciences	Positive

Eliem Therapeutics has a beta of -0.39, suggesting that its stock price is 139% less volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.19, suggesting that its stock price is 119% less volatile than the broader market.

Promis Neurosciences has a consensus price target of $26.50, suggesting a potential upside of 156.04%. Given Promis Neurosciences' stronger consensus rating and higher possible upside, analysts plainly believe Promis Neurosciences is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

69.8% of Eliem Therapeutics shares are owned by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by company insiders. Comparatively, 1.5% of Promis Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Promis Neurosciences beats Eliem Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Promis Neurosciences compare to Enanta Pharmaceuticals?

Promis Neurosciences (NASDAQ:PMN) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

In the previous week, Promis Neurosciences had 11 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 12 mentions for Promis Neurosciences and 1 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 1.87 beat Promis Neurosciences' score of 0.75 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Promis Neurosciences	Positive
Enanta Pharmaceuticals	Very Positive

Promis Neurosciences has higher earnings, but lower revenue than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A
Enanta Pharmaceuticals	$65.32M	5.30	-$81.89M	-$2.59	N/A

Promis Neurosciences presently has a consensus price target of $26.50, suggesting a potential upside of 156.04%. Enanta Pharmaceuticals has a consensus price target of $20.29, suggesting a potential upside of 70.47%. Given Promis Neurosciences' higher possible upside, equities research analysts clearly believe Promis Neurosciences is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Promis Neurosciences has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -89.56%. Enanta Pharmaceuticals' return on equity of -64.04% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Promis Neurosciences	N/A	-237.99%	-151.04%
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%

50.1% of Promis Neurosciences shares are owned by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 1.5% of Promis Neurosciences shares are owned by insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Promis Neurosciences has a beta of -0.19, indicating that its share price is 119% less volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

Summary

Enanta Pharmaceuticals beats Promis Neurosciences on 10 of the 16 factors compared between the two stocks.

Get Promis Neurosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PMN vs. The Competition

Export

Metric	Promis Neurosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$92.84M	$3.40B	$6.74B	$12.07B
Dividend Yield	N/A	2.25%	2.67%	5.67%
P/E Ratio	-0.71	19.82	24.21	24.42
Price / Sales	N/A	305.69	512.04	109.94
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	-17.84	8.32	10.66	6.83
Net Income	-$39.72M	$23.94M	$3.57B	$337.67M
7 Day Performance	6.59%	1.84%	0.58%	1.17%
1 Month Performance	-0.38%	-0.04%	1.54%	3.16%
1 Year Performance	-20.31%	44.82%	25.40%	30.58%

Promis Neurosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PMN Promis Neurosciences	4.016 of 5 stars	$10.35 flat	$26.50 +156.0%	-20.3%	$92.84M	N/A	N/A	5	Gap Up
AVIR Atea Pharmaceuticals	0.7322 of 5 stars	$4.39 +0.7%	N/A	+42.1%	$348.92M	N/A	N/A	70
IRD Opus Genetics	3.0583 of 5 stars	$3.89 -4.7%	$10.67 +174.2%	+316.5%	$336.87M	$11.98M	N/A	14	Analyst Revision
LXEO Lexeo Therapeutics	2.0643 of 5 stars	$4.13 -2.6%	$20.14 +387.7%	+10.9%	$332.93M	N/A	N/A	58	Positive News Analyst Upgrade
ELYM Eliem Therapeutics	N/A	$11.14 +3.4%	N/A	+807.9%	$331.29M	N/A	N/A	9	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PMN) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Promis Neurosciences (PMN) Competitors

PMN vs. AVIR, IRD, LXEO, ELYM, and ENTA

How does Promis Neurosciences compare to Atea Pharmaceuticals?

Summary

How does Promis Neurosciences compare to Opus Genetics?

Summary

How does Promis Neurosciences compare to Lexeo Therapeutics?

Summary

How does Promis Neurosciences compare to Eliem Therapeutics?

Summary

How does Promis Neurosciences compare to Enanta Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMN vs. The Competition

Promis Neurosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Promis Neurosciences (PMN) Competitors

PMN vs. AVIR, IRD, LXEO, ELYM, and ENTA

How does Promis Neurosciences compare to Atea Pharmaceuticals?

Which has higher earnings and valuation, PMN or AVIR?

Which has more volatility and risk, PMN or AVIR?

Do analysts rate PMN or AVIR?

Does the media favor PMN or AVIR?

Do institutionals and insiders hold more shares of PMN or AVIR?

Is PMN or AVIR more profitable?

Summary

How does Promis Neurosciences compare to Opus Genetics?

Which has preferable earnings and valuation, PMN or IRD?

Which has more volatility and risk, PMN or IRD?

Do analysts rate PMN or IRD?

Is PMN or IRD more profitable?

Do institutionals and insiders believe in PMN or IRD?

Does the media prefer PMN or IRD?

Summary

How does Promis Neurosciences compare to Lexeo Therapeutics?

Do insiders & institutionals have more ownership in LXEO or PMN?

Do analysts recommend LXEO or PMN?

Which has preferable valuation & earnings, LXEO or PMN?

Which has more volatility & risk, LXEO or PMN?

Is LXEO or PMN more profitable?

Does the media refer more to LXEO or PMN?

Summary

How does Promis Neurosciences compare to Eliem Therapeutics?

Which has stronger earnings and valuation, ELYM or PMN?

Is ELYM or PMN more profitable?

Does the media refer more to ELYM or PMN?

Which has more volatility and risk, ELYM or PMN?

Do analysts recommend ELYM or PMN?

Do institutionals and insiders have more ownership in ELYM or PMN?

Summary

How does Promis Neurosciences compare to Enanta Pharmaceuticals?

Does the media prefer PMN or ENTA?

Which has preferable valuation & earnings, PMN or ENTA?

Do analysts prefer PMN or ENTA?

Is PMN or ENTA more profitable?

Do insiders & institutionals hold more shares of PMN or ENTA?

Which has more risk & volatility, PMN or ENTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMN vs. The Competition

Promis Neurosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools